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Lung hydatidosis is a zoonosis related to infection by the Echinococcus tapeworm species. Lung 
involvement in this condition is second only to the liver Echinococcosis. Diagnosis commonly results 
from an incidental finding in a routine X-ray evaluation because of the delayed growth of the cysts. 
Moreover, a uniform treatment regimen or approach may not be feasible because of the variability of 
pulmonary echinococcosis. In this narrative review we aimed to summarize the main features of lung 
hydatidosis with a perspective on medical and surgical treatment. 
Methods 
A literature search was performed using the PubMed database and the Cochrane library. Search terms 
included “pulmonary echinococcosis” and “lung hydatidosis”. The MeSH terms were “lung” [All 
Fields] AND {“echinococcosis” [MeSH Terms] OR (“hydatidosis” [All Fields] OR “pulmonary” [All 
Fields] AND “echinococcosis” [All fields] OR “hydatidosis”. A search period of September 1980 to 
May 2020  was selected to compare studies from different decades, given the changes in pulmonary 
echinococcosis management.  
Results 
A uniform treatment regimen or approach may not be feasible because of the variability of pulmonary 
echinococcosis. No clinical trials have compared all the different treatment modalities. Cyst size, 
characteristics, position in the lung and clinical presentation and the availability of medical/surgical 
expertise and equipment are the mainstays of echinococcosis management. When feasible, surgery is 
still the main therapeutic option to remove the cysts; antiparasitic drugs may minimize complications 
during high-risk surgery or be used as a definitive therapy in certain cases with major 
contraindications to surgery. 
Conclusions 
Lung hydatidosis management must become less heterogeneous. We support treatment targeted to 
the individual on the basis of the clinical situation, host factors and surgical risk. Strict cooperation 
in this process between infectious disease specialists and surgeons may optimise best practices to 




Human pulmonary echinococcosis is a zoonotic disease related to infection by the Echinococcus 
tapeworm species [1]. Lung involvement in this condition is epidemiologically secondary only to 
liver disease and has been found in about 20% of infected patients [2]. Most cases of echinococcosis 
are related to Echinococcus granulosus [3], and human infection is widespread and considered a 
significant public health issue in countries where dogs, the main definitive hosts, live in close contact 
with humans and livestock [4]. Diagnosis commonly results from an incidental finding in a routine 
X-ray evaluation because of the delayed growth of the cysts, becoming symptomatic with the rupture 
of the cysts and occasionally with the development of immune-mediated reactions against 
Echinococcus spp. [1-2, 4]. A uniform treatment regimen or approach may not be feasible because of 
the variability of pulmonary echinococcosis [4-5]. Notwithstanding its frequency and widespread 
endemicity, the knowledge of and literature on lung hydatidosis must be expanded. Furthermore, a 
standard of care has not been widely endorsed or implemented outside referral centres [1-2, 4-5]. We 
aimed to summarize the main features of and evidence on lung hydatidosis from the perspective of 
medical and surgical treatment. 
Methods 
A literature search was performed using the PubMed database and the Cochrane library. Search terms 
included “pulmonary echinococcosis” and “lung hydatidosis”. The MeSH terms were “lung” [All 
Fields] AND {“echinococcosis” [MeSH Terms] OR (“hydatidosis” [All Fields] OR “pulmonary” [All 
Fields] AND “echinococcosis” [All fields] OR “hydatidosis”. A search period of 1 September 1980 
to 1 April 2020  was selected to narratively review studies from different decades, given the changes 
in pulmonary echinococcosis management.  
Epidemiology 
Human echinococcosis is widespread throughout the world and has some peculiarity between cystic 
and alveolar echinococcosis (CE and AE, respectively) [6-7]. E. vogeli and E. oligarthra, belonging 
to the so-called neotropical type of echinococcosis, are limited to South America, and new cases are 
rarely reported [8-10]. Thompson and Lymbery (1988) suggested the presence of intraspecific 
variants of CE and introduced the concept of E. granulosus sensu lato complex [11]. The latter 
includes genotypes from G1 to G10 (with the uncertain existence of G9), subdivided according to 
mitochondrial DNA sequences (mtDNA). Its taxonomy merges the genotypes into five species: E. 
granulosus sensu stricto (G1, G2 and G3), Echinococcus equinus (G4), Echinococcus ortleppi (G5), 
Echinococcus canadensis (G6, G7, G8 and G10) and Echinococcus felidis [2]. According to a recent 
summary of 1,661 genotyped cases published worldwide, the majority are caused by E. granulosus 
sensu stricto [2]. Molecular identification of human CE cases is strongly recommended for a better 
understanding of the epidemiology, pathology and natural history of infection, particularly in areas 
of sympatry, where multiple etiological agents of CE exist [2] 
Cystic Echinococcosis (CE) 
Attempts to map the incidence and prevalence of CE in humans have found a lack of accurate case 
records [3]. For example, the European registry of CE (ERCE) was recently launched [12], born of 
the Human cystic Echinococcosis ReseArch in CentraL and Eastern Societies (HERACLES) project 
[13]. Most of the available data concerned cases transmitted by domestic intermediate hosts [3]. 
Nevertheless, with the above limits, CE’s epidemiology seems to be stable in the last 20 years, and 
the latest estimate of the global burden of CE is 188,000 new cases per annum [3]. Eastern China, 
Central Asia, South America, the Mediterranean and eastern Africa are endemic areas [3, 14-19]. CE 
has been declared eliminated from New Zealand, and some regions of Australia, such as Tasmania, 
have been provisionally declared free of the disease in humans [1, 20] although it is still found in 
Tasmanian wild and rural dogs [20]. In Western Europe [21] and North America [22], CE is not 
considered a significant cause of morbidity or mortality, and most human cases are imported, 
although an autochthonous cycle with low prevalence is present. Sporadic cases in the USA were 
reported by Moro et al. [22] in Alaska, California and Utah. In northern Europe, the United Kingdom 
is endemic for E. granulosus with the highest incidence in the western isles, Shetland and Highlands, 
while Ireland is believed to be nonendemic for CE [21]. In southern Europe, which includes Portugal, 
Spain, France, Greece and Italy, CE is the most critical helminth zoonosis, with a life cycle involving 
dogs and farm livestock as definitive and intermediate hosts, respectively [21]. 
Alveolar Echinococcosis (AE) 
Although AE is generally considered a parasite of the northern hemisphere, the criteria for designation 
of a region as endemic for E. multilocularis have not been consistently defined, largely due to marked 
global differences in surveillance efforts and sensibility of diagnostic tools, as well as variability in 
host assemblages and host prevalence [23]. The global annual incidence of AE is estimated to be 
18,200 cases, 91% of which occur in China, notably on the Tibetan plateau [24]. AE is also endemic 
in Central Asia, and both E. multilocularis and E. granulosus are highly represented in Kazakhstan 
and Kyrgyzstan [24-25]. Human cases of E. multilocularis have recently been found in European 
countries previously considered to be free of AE,for example, in the previously unrecognized areas 
of endemicity of France, Switzerland, Germany, and Austria [26-29]. Currently, approximately 1600 
new cases of AE have been reported in Europe up to 2019 [24]. AE had not been considered a major 
human health issue in North America, except in Alaska, until recently, and E. multilocularis has not 
been reported in Mexico or the southern United States [24, 30].  
Life Cycle 
Hosts for the cestodes tapeworm may be subdivided into three categories: definitive, intermediate 
and accidental [31]. The definitive hosts are carnivores, notably dogs, cats and wild canids, in which 
adult tapeworms (2.0–7.0 mm length for E. granulosus and 1.2–4.5 mm for E. multilocularis) inhabit 
the small intestine [31-33]. Domestic animals and other warm-blooded vertebrates, such as sheep, 
goats, cattle, horses, camels and pigs, act as intermediate hosts, ingesting eggs released by carnivores; 
they carry predominantly Echinococcus granulosus. Rodents, deer, moose, reindeer and bison are 
intermediate hosts of E. multilocularis [34-37]. Humans may accidentally act an intermediate host 
although they do not have a clear role in the biological cycle [34-37] (Figure 1). 
A complete life cycle takes four to seven weeks. In the small intestine of definitive hosts, cestodes 
scolex present a double row of hooklets, which play a pivotal role in the attachment to the intestinal 
mucosa. Cestodes scolex have at least two proglottids (the number of proglottids changes between 
causative agents, from three to six in E. granulosus and from two to six in E. multilocularis), which 
contain numerous eggs. The eggs are passed out through the host’s faeces and released into the 
environment [31]. 
The intermediate hosts ingest the eggs while feeding, which settle in their gut and release oncospheres 
that are subsequently transported through the blood or lymph to primary target organs. Lymph enters 
the portal circulation via the intestinal wall and travels to the visceral organs’ capillary bed (primarily 
the liver, secondarily the lungs) [36-37]. In the organs, oncospheres become vesicles (metacestodes) 
and grow concentrically into a fluid-filled cyst. Hydatic cysts for E. granulosus are initially fluid 
filled, unilocular and rich with hundreds to thousands of protoscolices; the morphology of E. 
multilocularis cysts differs, with masses of numerous small cysts interconnected by dense connective 
tissue [32-33]. The cysts consist of an inner germinal and nucleated syncytial layer supported 
externally by a carbohydrate-rich acellular laminated layer of variable thickness, which is surrounded 
by a host-produced fibrous adventitial layer [31, 38-39]. Daughter cysts may develop within larger 
primary cysts. Protoscolices (or protoscolex in E. multilocularis) are the preceding step before the 
adult worm when reuniting with the definitive host’s intestine [38-39]. 
Clinical Features and Diagnosis 
Pulmonary echinococcosis has been described in about 20% of infected patients, and the lungs are 
the second target organ after the liver, which is affected in about 70% of cases reported [4]. Most of 
the infections in both lungs and liver are due to Echinococcus granulosus sensu lato complex, 
unlike E. multilocularis, in which almost all primary lesions are found in the liver [37]. Most 
patients have single-organ involvement with solitary cysts (cysts range from 1 to more than 20 cm 
in diameter), but 10% to 15% of patients have two or more involved organs [5]. Lungs are affected 
by multiple cysts in 20% to 30% of patients and are frequently located in the lower lobes, more 
often posteriorly than anteriorly and more often in the right lobes (approximately 50% have 
occurred in the right lung) [4-5, 40]. Subjects with pulmonary echinococcosis are usually children 
or young adults (20 to 40 years old): in these high-risk groups, lungs may be involved in 50% 
of Echinococcus spp. infections [41-42].  
Pulmonary disease may be classified into three main clinical scenarios: asymptomatic early phase, 
symptomatic stage and complicated late phase. 
Asymptomatic early phase 
The early stages of CE and AE usually do not cause symptoms, and CE cysts and AE lesions can 
remain undetected for 10 to 15 years [4-5]. Children and young adults are often asymptomatic 
despite the presence of large lesions, probably because of anatomical features such as higher 
elasticity of the lung parenchyma and the rib cage and weaker immune response against parasites 
[41-43]. Subclinical or late-presenting symptoms are typical for most AE and CE patients because 
of the slow annually growth of cysts (ranging from 1 to 5 cm per year), especially in 
immunocompetent patients [4-5, 40]. The faster growth of cysts in CE patients with AIDS suggests 
that immune suppression may play a role in CE progression [30]. Genetic variation of the human 
leukocyte antigen (HLA) system is associated with the occurrence or progression of AE lesions in 
humans; patients with the HLA-DR3 DQ2 haplotype were shown to have more severe disease and a 
more pronounced Th2-type immune response, associated with a more profound tolerance status 
[30]. 
Symptomatic Stage 
Various symptoms are loco-regional and may be due to compression or damage to bronchia, 
vessels, rib cage or mediastinal organs: most symptoms of pulmonary CE are caused by mass effect 
exerted by the cysts on nearby tissues [44-45]. Cough, chest pain, dyspnea and hemoptysis are the 
most common symptoms reported [4-5, 46-47]. Less frequent are malaise, nausea, vomiting and 
thoracic deformations [4-5, 46-47]. Most pulmonary cysts are located in the lower lobes, more often 
posteriorly than anteriorly [48]. Approximately 50% of cysts are localized in the right lung, 40% in 
the left lung, and 10% bilaterally [48-49]. 
Late Complicated Stage  
The presence of any complications changes the clinical presentation, either causing new symptoms 
or increasing the severity of existing symptoms.   
The main complication is cyst rupture; in any organ, cyst rupture can induce fever, urticaria, 
eosinophilia and anaphylactic shock [50]. Lung cysts may break, causing cyst material containing 
fragments of larval tissue and protoscolices to be spilt and eventually flow either into the bronchial 
tree, producing cough, chest pain, hemoptysis or vomica [51], or into the pleural cavity, causing 
simple or tension pneumothorax, pleural effusion or empyema [52]. Mediastinal cysts may erode 
into adjacent structures, causing bone pain, haemorrhage or airflow limitation [53-54]. Eosinophilia 
and allergic reactions are very uncommon in AE because of the different structure of the parasitic 
lesions from CE, with dense fibrosis preventing vesicle fluid leakage; these reactions may be 
observed in rare cases of dissemination of lesion fragments into the blood [55-57]. Other potential 
clinical effects of hydatid infection include immune complex–mediated disease, glomerulonephritis 
leading to nephrotic syndrome [58], and secondary amyloidosis [59]. Another significant 
complication is the superinfection of the cyst, manifesting as a pulmonary abscess with poorly 
defined margins. Ruptured cysts may become infected with bacteria or with saprophytic or invasive 
fungi, which are serious complications [60-63]. Hydatid disease causes recurrent acute pulmonary 
embolism in rare cases [64]. Transdiaphragmatic migration of hydatid disease from the posterior 
segments of the right hepatic lobe has been reported to be a common complication and is probably 
related to their proximity to the diaphragm [65]. 
Diagnosis 
Radiological diagnosis 
The first step in assessing lung hydatidosis is taking a chest X-ray [66]. Uncomplicated cysts appear 
on chest radiographs as a rounded or ovalized masses with smooth borders and uniform density and 
are surrounded by healthy lung tissue [67]. Indirect signs of lung hydatidosis on close structures (e.g., 
trachea, bronchi) are visible if the dimensions of cysts are relevant, such as a shift of the mediastinum, 
pleural reactions or compression of the lung parenchyma causing atelectasis [67-68]. X-rays can 
easily detect calcification of pulmonary cysts, but it is rare to find calcification in pulmonary 
echinococcosis [68-69]. Complicated cysts, such as broken cysts, present with typical diagnostic but 
also different signs [67-69]. Typical signs with variable frequencies between case series are visible 
in X-rays. The crescent or meniscus sign occurs as a result of air introduced between the pericyst and 
the exocyst, causing the erosion of bronchioles for cyst growth: some authors consider it as an 
alarming sign of impending rupture [30, 67-69]. The ingress of air within the cyst may also appear as 
parallel arches of air with an appearance like an onion peel, which is called Cumbo’s sign. [30, 67-
68]. The presence of an air/fluid level may be interpreted as a theoretical communication between the 
cyst and the tracheobronchial tree [30, 67-68]. The water lily or Camelotte sign follows the collapse 
of the entire endocyst, in which the crumpled internal layer floats freely in the cyst fluid [30]. The 
fluid component might be expelled in the tracheobronchial tree, and the remaining solid component 
of the cyst gives rise to a mass within a cavity, or Monod's sign [67-69]. 
A CT scan is useful to better identify specific details of the lesions and their surrounding structures, 
helping to exclude alternative differential diagnoses: in intact cysts, a CT scan may reveal a thin rim 
defining the perimeter [48]. Small cysts, undetectable by a chest X-ray, may be detected with CT 
scanning’s better imaging definition, which is also valuable in the case of complicated cysts; for 
example, it can identify a cyst wall defect in a ruptured cyst [70]. Infected cysts show in CT scans as 
poorly defined masses with increased internal density and contrast enhancement around the cyst wall 
(the ring enhancement sign) after the injection of a contrast substance. CT scanning can elucidate the 
cystic nature of the lung mass and provide accurate localization to plan the surgical treatment of 
complicated cysts [70-71]. 
Ultrasonography is helpful in most cases, providing excellent images only when the cysts are close 
to the pleural surface [72]. Most importantly, however, ultrasound examination of the liver may reveal 
concomitant liver involvement in up to 15% of individuals with lung CE [73]. Contrast-enhanced 
ultrasonography, based on pulsating blood flow imaging, may be used to detect small AE lesions and 
differentiate them from abscesses and tumours [72-73]. 
With magnetic resonance imaging (MRI), cysts show low signal intensity in T1-weighted images and 
high signal intensity in T2-weighted images: signal characteristics of a hydatid cyst may differ 
depending on the developmental phase [67-68]. FDG-positron emission tomography (FDG-PET) has 
become the favoured reference tool to evaluate their metabolic activity [74]. In CE, MRI appears to 
be of better diagnostic value than CT scanning, and both procedures are complementary to AE and 
should be performed to provide sufficient information for therapeutic decision-making [67-68]. 
Serological diagnosis 
Major antigens for immunodiagnosis are contained in the hydatid fluid [75]. In the past, the Casoni 
intradermal test has exhibited low specificity and sensitivity; furthermore, poor standardization and 
ethical issues regarding the injection of reagents of animal origin into humans have considerably 
limited the use of skin tests for echinococcosis diagnosis [76]. Reported sensitivities  of serological 
methods for testing CE patients, confirmed by surgical resection, vary from 60% to 90% [75, 77-78]. 
The encystment of the metacestode prevents the stimulation of antibody-producing cells, which could 
induce false-negative results of serology tests [75, 77-78]. 
 For both CE and AE, serology is now used only to confirm imaging results; it may also provide some 
insight into the infection pressure on a given population (e.g., children) in a particular geographic 
area [77-78]. The Expert Consensus of the WHO-IWGE also uses serology results to determine 
“possible” and “probable” cases [79]. 
Treatment 
A uniform treatment regimen or approach may not be feasible because of the variability of pulmonary 
echinococcosis. No clinical trials have compared all the different treatment modalities. Cyst size, 
characteristics, position in the lung and clinical presentation and the availability of medical/surgical 
expertise and equipment are the mainstays of echinococcosis management . Many patients with lung 
lesions were admitted to hospital because of complications, mainly infection.  
Surgical approach 
The aim of surgical treatment of hydatid cysts is the complete evacuation of the cyst, the removal of 
the endocyst to avoid intraoperative contamination, the closure of the pericystic cavity to prevent 
prolonged air leak and empyema and the preservation of healthy lung parenchyma [80-82]. All the 
abovementioned precautions should be taken perioperatively to avoid accidental rupture of the cyst. 
If anaphylactic shock occurs as a result of cyst rupture, steroids and octreotide infusion must be 
administered [80-81].  
For the removal of the cyst, different surgical techniques may be considered. The Ugon enucleation 
technique was proposed in 1952 and is suitable for a relatively small cyst. The surrounding area is 
fixed with packs soaked in a scolicidal agent (povidone iodine or hypertonic saline). An incision is 
made over the adventitia layer of the cyst to observe the underlying white-coloured laminated 
membrane [81-83]. The anaesthetist is then asked to apply positive pressure ventilation to the 
ipsilateral lung. This manoeuvre should cause the cyst to be expelled intact from the cavity. The 
remaining cyst cavity is irrigated with an isotonic saline solution, and air leaks are obliterated using 
non-absorbable stitches [81].  
Cystotomy with capitonnage (Barrett’s method) was proposed in 1952. The enucleation step 
involves careful incision of the lung parenchyma, avoiding rupture of the cyst. The cyst is carefully 
dissected with blunt dissection and positive pressure ventilation, which assists the enucleation 
process. The cavity walls are approximated with either interrupted non-absorbable purse-string 
sutures or the walls of the cyst. Finally, the healthy parenchymal ends are approximated with non-
absorbable sutures [80-82]. 
Posadas’ method is a modification of Barrett’s procedure and consists of the closure of the airway 
openings before capitonnage. The Perez-Fontana method of pericystectomy was proposed in 1953, 
and it involves excising the hydatid cyst along with the pericyst, which is adhered to the normal 
lung parenchyma [82]. There is now a consensus that the host tissue generates the pericyst in 
response to the cyst, and there is no need to remove it, mainly because its excision leads to a more 
prolonged air leak.  
The needle aspiration method (the Figuera technique) entails no risk of cyst rupture or 
contamination of the pleura [80-81]. To prevent contamination, a few towels soaked in povidone-
iodine solution are placed around the cyst. The syringe and catheters are outside the chest cavity. 
Then the pericyst is incised with scissors, and the fluid within the cyst is aspirated. When the cyst is 
decompressed, the surrounding parenchyma is incised, and the endocyst is removed [81-83]. The air 
leaks are obliterated with absorbable sutures. Although parenchyma-sparing procedures are 
preferred, sometimes segmentectomy, lobectomy and even pneumonectomy are required. Lung 
resections for the treatment of hydatid cyst disease of the lung may be required in rare cases. In the 
literature, the rate of lobectomy ranges from 0.5% to 45% [80]. Indications for lobectomy are a 
large cyst involving more than 50% of the lung, a cyst complicated by suppurative pulmonary 
infection not responding to medical treatment, multiple unilobar cysts and parenchymal destruction 
and fibrosis of lung tissue in chronic cases [80-83].  
The best surgical approach depends on the size of the cyst and whether the cyst is single or multiple, 
unilateral or bilateral, intact or ruptured and associated with a liver dome cyst or with destroyed 
lung parenchyma [81-83]. Commonly, thoracotomy is the selected approach for the resection of 
hydatid cysts of the lung. Besides, Median sternotomy is useful for the treatment of bilateral 
anterior hydatid cysts [80-82]. Moreover, the preferred surgical approach to liver cysts penetrating 
the diaphragm into the right lower or middle lobe is a standard thoraco-laparotomy.  Nevertheless, 
in last years  minimally invasive thoracoscopic approaches, named video-assisted thoracic surgery 
(VATS) (either, uniportal or multiportal), demonstrated to be a feasible and safe treatment strategy, 
especially for the treatment of small and peripheral cysts. [80-84]. Reported advantages of VATS 
were shorter surgical time, decreased length of hospital stay, lower experienced pain, and reduced 
surgical morbidity. [85-87] Almost Certainly, in the next future, those minimal invasive approaches, 
and probably also robotic-assisted surgery, will be more diffusively adopted for surgical treatment 
of lung hydatidosis, similarly as it occurs in lung cancer disease [88]. .  
Medical treatment 
Antiparasitic drug treatment may be a first definitive option or an adjunctive therapy following 
surgery [79]. Albendazole has proven to be the first choice for Echinococcus spp. infections, but an 
alternative option is mebendazole. Praziquantel is less effective but has been studied in combination 
with benzimidazoles.  
Historically, variable periods (from two to four weeks) of anti-helminth chemotherapeutic agents 
are prescribed preoperatively to prevent disease recurrence due to spillage at the time after surgical 
treatment of liver hydatidosis, and albendazole plus praziquantel has been found to be superior in its 
scolicidal activity when compared with albendazole alone [89-90]. However, at this time, the 
efficacy of preoperative or post-operative therapy has not been clearly studied in pulmonary 
hydatidosis. As a convention, by translating evidence from liver hydatidosis studies, preoperative 
albendazole for two to four weeks is prescribed for preventing the post-operative regrowth ensuing 
on intra-operative spillage [89-91]. Despite that, the optimal duration of preoperative anti-helminths 
treatment in pulmonary echinococcosis remains unclear. 
 
Benzimidazoles  
Benzimidazoles may be the first option in small, uncomplicated lung cysts. The cut-off size for the 
diameter of lung lesions is not standardized, unlike for liver cysts, for which Albendazole (or 
Mebendazole) is suggested for diameters < 5 cm (CE1, WHO classification). Brunetti et al. [79], in 
an expert consensus, suggested that benzimidazoles should be avoided pre-operatively in larger lung 
cysts. A study [84] on the clinical experience of surgical therapy for thoracic hydatidosis reported an 
antiparasitic role of albendazole for multiple intrathoracic cysts (with or without liver lesions). 
Medical treatment is the preferred choice when surgery is not available or when complete removal is 
not feasible. 
Albendazole 
Albendazole (Table 1) is an anthelmintic benzimidazole carbamate given orally but poorly absorbed 
via this route of administration (< 5%) and, because of its insolubility, has not been administered 
parenterally [92]. In contrast with intestinal helminth species, for which drug absorption is not 
necessary, systemic parasites require an extended treatment to produce a sufficiently therapeutic drug 
[92-93]. Albendazole sulfoxide, the main metabolite of albendazole, is the main agent in systemic 
infections, with an elimination half-life of 8–12 hours, and it is moderately bound to plasma proteins 
(70%) [92-93]. Albendazole acts first through the inhibition of parasite beta-tubulin polymerization 
and, second, through downstream effects, such as fumarate reductase inhibition and the interruption 
of energy pathways that result in parasite death [92]. 
Culture and in-vitro tests of the susceptibility of helminths to albendazole are often impossible, and 
anti-parasitic activities have been extrapolated by empirical testing in vivo in humans or by 
extrapolation from the doses used for domestic animal species [93]. 
In humans, definitive evidence of clinical resistance is lacking, but for Echinococcus spp., prolonged 
infections and intermittent treatment with anti-helminthic drugs might provide ideal circumstances 
for the development of resistance. On the other hand, transmission to other individuals would not 
occur as human infection represents a dead end for the parasite life cycle [93]. 
Albendazole presents a hepatic metabolism, but there is a lack of information about dose adjustment 
in liver impairment. [93-94]. Cotting et al. [95] presented five patients with echinococcosis and 
significant extrahepatic biliary obstruction, for whom the absorption and clearance of albendazole 
were significantly delayed and Cmax was doubled. Albendazole diffuses well in various tissues and 
has been detected in urine, bile, liver, cyst walls, cyst fluid and cerebrospinal fluid and is highly 
correlated with drug’s concentrations in plasm [93-94].  
Mebendazole 
Mebendazole (Table 1) belong to the same anthelmintic class as albendazole, which has now largely 
replaced albendazole for Echinococcus infections. Its oral bioavailability is near 5–10%, but with 
tracer doses of [3H]-mebendazole administered orally and intravenously, the absolute bioavailability 
was estimated to be 22% [96]. 
There are no clinical data on dose adjustment in renal impairment. Even with renal impairment, 
mebendazole is largely metabolized in the liver, so dose adjustment is not likely to be required in 
most cases [97]. Nevertheless, some authorities have advised caution during long-term therapy in 
patients with hepatic echinococcosis because metabolism may be impaired in such patients, leading 
to elevated levels of the parent drug and possible toxicity [96]. Moreover, plasma concentrations were 
reported to be higher in a patient with cholelithiasis than in normal subjects [97-98]. The metabolites 
are excreted principally in the urine, and in patients receiving long-term, high-dose of mebendazole, 
metabolites might accumulate [98-99].  
Mebendazole can be measured in a number of tissues, most notably the liver, and in echinococcal 
cysts, where the concentrations correlated well with the free mebendazole plasma concentrations four 
hours after dosing [100]. There is significant interindividual variability in the bioavailability and 
metabolism of mebendazole, and there is little data to directly correlate the clinical activity of 
mebendazole with its pharmacokinetic and pharmacodynamic parameters [101]. 
Praziquantel 
Praziquantel (Table 1) is a pyrazinoisoquinoline derivative found to be active against a wide range 
of trematode and cestode helminths [102]. Praziquantel is currently the mainstay treatment for 
schistosomiasis and opisthorchiasis.  Its absorption after oral administration is up to 80%, and it has 
almost total renal excretion. Its short plasma half-life requires administration three times per day 
[102-103].  
Monotherapy with praziquantel has no activity against cystic echinococcosis. A small trial combining 
praziquantel and albendazole for six months resulted in a superior rate of cyst disappearance (47.4% 
vs. 36.4%) for up to three years, compared to 22 historical controls, which received albendazole alone 
[104]. This observation remains to be confirmed. In vitro and in vivo praziquantel theoretically has a 
role as a protoscolicide in preventing the dissemination of cyst content [105]. 
It is of note that praziquantel has a well-recognized effect on the pharmacokinetics of albendazole, 
increasing serum and intracyst concentrations of albendazole sulfoxide by inhibiting hepatic 
catabolism [106]. The relevance of this observation to clinical efficacy has yet to be established. 
Conclusions 
There is a growing tendency to manage uncomplicated cysts according to one of the main treatment 
options (e.g. watch and wait, surgical treatment, medical treatment, or both medical and surgical 
treatment) notably on the basis of host factors, comorbidities and cyst stage, size and location. 
Medical treatment (alone or combined) is the preferred choice when surgery is not available or 
when complete removal is not feasible [107]: in our opinion, antiparasitic drugs may be valuable in 
three specific instances: 1) in single, small, uncomplicated cysts, 2) in disseminated diseases or 3) 
patients with poor surgical risk. The cyst may be disrupted by medical therapy, but membranes 
associated with cysts carry a significant risk of infection. [108-109]. 
For pulmonary hydatidosis, surgery remains indicated in most cases: operative mortality remains 
acceptable (1–2%), and morbidity is low [109-110]. The recurrence rate varies from 1.9% to 2.9%, 
depending on the series [109-111].  
A standard of care has not been widely endorsed or implemented outside referral centres because of 
a lack of well-designed clinical trials to respond to this need and to consolidate the best practices for 
treating hydatidosis (Figure 2). Complicated cysts require a case-by-case decision for appropriate 
management [108-110]. In support of surgical management, alongside the removal of the parasite, 
surgery may also act on associated parenchymal, bronchial, or pleural damage. Nevertheless, 
surgery must be as conservative as possible; resection is proposed only for severe and irremediable 
lung damage, and lobectomy is necessary in less than 10% of the patients [111-112]. Proper 
management of hydatidosis may also be considered from an infection control perspective. 
Monitoring the transmission of Echinococcus spp. has a pivotal role in public health, and efforts 
should be focused on strengthening and improving control programs in endemic areas to reduce the 
incidence and burden of echinococcosis [113-114]. 
In conclusion, hydatidosis management must become less heterogeneous. We support treatment 
targeted to the individual on the basis of the clinical situation, host factors and surgical risk. Strict 
cooperation in this process between infectious disease specialists and surgeons may optimise best 
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